Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237894 | PMC |
http://dx.doi.org/10.1016/j.amjmed.2020.04.017 | DOI Listing |
Heart
June 2024
Digestive Disease Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
Background: We aimed to investigate the effectiveness of fixed-dose combination therapy (polypill) for primary and secondary prevention of major cardiovascular diseases in a typical rural setting.
Methods: The PolyPars Study is a two-arm pragmatic cluster-randomised trial nested within the PARS cohort study, including all residents aged over 50 years in the entire district in southern Iran. The 91 villages underwent random allocation into two arms: the control arm, encompassing 45 clusters, was subjected to non-pharmacological intervention (educational training on healthy lifestyle), whereas the intervention arm, comprising 46 clusters, received the non-pharmacological interventions in conjunction with a once-daily polypill tablet.
Medicina (B Aires)
December 2022
Servicio de Cardiología, Sanatorio Güemes, Buenos Aires, Argentina.
Unlike medications that contain fixed-dose combinations, such as those recommended by clinical guidelines for treating high blood pressure, the so-called polypills contain several drugs that simultaneously treat two or more cardiovascular conditions or risk factors. They were proposed 2 decades ago, both for primary and secondary prevention with the hypothesis that they could have wide dissemination and population penetration, improving the use of therapeutics with proven benefits individually, thanks to an increase in patient adherence by reducing the number of daily tablets and also by having an equal or lower cost. In this simple review, we present a look at risk stratification different from that posed by clinical scores and summarize the benefits of polypills in the treatment of risk factors and in the reduction of major cardiovascular events.
View Article and Find Full Text PDFProg Cardiovasc Dis
September 2022
Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, United States of America. Electronic address:
Prior studies have reported improvements in population-level risk factor burden and cardiovascular disease (CVD) outcomes using polypills for CVD risk reduction. However, a comprehensive assessment of the impact of polypills on CVD outcomes, mortality, adherence, and side effects across different settings has not previously been reported. We performed a systematic review and meta-analysis of randomized controlled trials examining the association between polypill therapy and CVD outcomes published before February 2021.
View Article and Find Full Text PDFNutrients
September 2021
The George Institute for Global Health, University of New South Wales, Sydney, NSW 2050, Australia.
Widespread use of reduced-sodium salts can potentially lower excessive population-level dietary sodium intake. This study aimed to identify key barriers and facilitators to implementing reduced-sodium salt as a population level intervention. Semi-structured interviews were conducted with key informants from academia, the salt manufacturing industry, and government.
View Article and Find Full Text PDFAm J Med
October 2020
Urban Health Collaborative; Department of Epidemiology and Biostatistics, Drexel Dornsife School of Public Health, Philadelphia, Penn.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!